Published in J Pharmacokinet Pharmacodyn on October 26, 2011
Merging systems biology with pharmacodynamics. Sci Transl Med (2012) 1.39
Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis. CPT Pharmacometrics Syst Pharmacol (2012) 1.06
Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study. CPT Pharmacometrics Syst Pharmacol (2016) 0.82
Pharmacokinetic/pharmacodynamic modeling in inflammation. Crit Rev Biomed Eng (2012) 0.81
Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models. CPT Pharmacometrics Syst Pharmacol (2015) 0.79
A Six-Stage Workflow for Robust Application of Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis. CPT Pharmacometrics Syst Pharmacol (2015) 0.77
Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats. Pharmacol Res Perspect (2015) 0.75
Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. J Pharmacokinet Pharmacodyn (2015) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
The osteoblast: a sophisticated fibroblast under central surveillance. Science (2000) 3.93
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J (2001) 2.81
Sex steroids and bone. Physiol Rev (2001) 1.88
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med (1993) 1.80
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol (2004) 1.77
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol (2007) 1.70
On the validity of the steady state assumption of enzyme kinetics. Bull Math Biol (1988) 1.67
Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone (2002) 1.64
Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab (1994) 1.63
Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001. Menopause (2010) 1.58
Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol (2001) 1.57
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone (2009) 1.57
A strategy for integrative computational physiology. Physiology (Bethesda) (2005) 1.48
Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45
Model structure and control of bone remodeling: a theoretical study. Bone (2008) 1.44
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.41
Vitamin D in health and disease: current perspectives. Nutr J (2010) 1.31
Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone (2003) 1.29
Female reproductive system and bone. Arch Biochem Biophys (2010) 1.19
The direct role of vitamin D on bone homeostasis. Arch Biochem Biophys (2008) 1.05
Age-related bone loss. A hypothesis and initial assessment in mice. Clin Orthop Relat Res (1995) 1.01
Impact of plasma-protein binding on receptor occupancy: an analytical description. J Theor Biol (2008) 0.97
Use of oral corticosteroids and risk of fractures. June, 2000. J Bone Miner Res (2005) 0.95
Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet (2010) 0.93
Mathematical modeling in bone biology: from intracellular signaling to tissue mechanics. Bone (2010) 0.92
New analogs of vitamin D3. Kidney Int Suppl (1999) 0.88
General analysis of mathematical models for bone remodeling. Bone (2010) 0.86
Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat (2009) 0.85
Impact of protein binding on receptor occupancy: a two-compartment model. J Theor Biol (2010) 0.84
Growth factors and bone formation in osteoporosis: roles for IGF-I and TGF-beta. Rev Rhum Engl Ed (1997) 0.83
Reproductive aging, menopause, and health outcomes. Ann N Y Acad Sci (2010) 0.83
Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy. Biosystems (2003) 0.83
1,25-dihydroxyvitamin D reduces parathyroid hormone receptor number in ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these receptors: relationship to adenylate cyclase activation. J Bone Miner Res (1991) 0.79
Phenomenological model of bone remodeling cycle containing osteocyte regulation loop. Biosystems (2006) 0.79
Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol (2006) 0.78
Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells. Am J Physiol (1996) 0.78
On allosteric control model of bone turnover cycle containing osteocyte regulation loop. Biosystems (2006) 0.77
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. J Clin Pharmacol (2014) 1.99
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol (2010) 1.71
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet (2011) 1.51
Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn (2006) 1.35
Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet (2009) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
The effect of the UK incentive-based contract on the management of patients with coronary heart disease in primary care. Fam Pract (2008) 1.28
What is the right dose for children? Br J Clin Pharmacol (2010) 1.24
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet (2002) 1.23
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther (2004) 1.12
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit (2009) 1.12
Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet (2012) 1.10
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today (2008) 1.07
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res (2007) 1.05
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther (2005) 1.05
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet (2009) 1.04
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol (2011) 1.03
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther (2007) 1.02
Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol (2014) 1.02
A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res (2013) 1.00
Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol (2010) 1.00
Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. Br J Clin Pharmacol (2013) 0.99
Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm (2011) 0.99
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet (2014) 0.98
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn (2012) 0.97
Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. Br J Clin Pharmacol (2013) 0.97
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia (2008) 0.96
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet (2012) 0.96
Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol (2002) 0.96
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn (2012) 0.96
Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant (2012) 0.95
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res (2007) 0.95
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet (2013) 0.95
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res (2012) 0.94
Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet (2011) 0.94
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol (2004) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol (2005) 0.94
Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet (2010) 0.93
Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology (2006) 0.93
Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother (2010) 0.93
Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet (2010) 0.93
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res (2012) 0.92
The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinol Metab (2004) 0.92
Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci (2011) 0.92
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients. Eur J Clin Pharmacol (2007) 0.91
Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos (2011) 0.91
Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol (2014) 0.91
Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target (2004) 0.89
Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit (2012) 0.89
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn (2013) 0.89
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci (2008) 0.88
Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov Today (2012) 0.88
Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J (2012) 0.88
Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions. J Pharmacokinet Pharmacodyn (2013) 0.87
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. Am J Obstet Gynecol (2007) 0.87
Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.87
Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig (2013) 0.87
Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility. Schizophr Res (2013) 0.87
High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/pharmacodynamic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.86
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther (2002) 0.86
Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J Pharmacol Exp Ther (2002) 0.86
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology (2006) 0.86
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology (2006) 0.86
Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit (2012) 0.86
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res (2011) 0.86
Ontogeny of hepatic glucuronidation; methods and results. Curr Drug Metab (2012) 0.85
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br J Pharmacol (2006) 0.85
Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology (2006) 0.85
A nonlinear feedback model capturing different patterns of tolerance and rebound. Eur J Pharm Sci (2007) 0.85
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. Mol Imaging Biol (2006) 0.85
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther (2004) 0.85
Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid. J Pharm Sci (2014) 0.85
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. J Pharmacol Exp Ther (2007) 0.85
Turnover modeling of non-esterified fatty acids in rats after multiple intravenous infusions of nicotinic acid. Dose Response (2009) 0.84
Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives. Eur J Pharm Sci (2003) 0.84
A pharmacodynamic turnover model capturing asymmetric circadian baselines of body temperature, heart rate and blood pressure in rats: challenges in terms of tolerance and animal-handling effects. J Pharmacokinet Pharmacodyn (2005) 0.84
Low but inducible contribution of renal elimination to clearance of propylene glycol in preterm and term neonates. Ther Drug Monit (2014) 0.84
In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement. J Control Release (2002) 0.84
Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat. Epilepsia (2004) 0.84
Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet (2011) 0.83
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. Antimicrob Agents Chemother (2007) 0.83
Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions. J Pharmacokinet Pharmacodyn (2010) 0.83
Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci (2006) 0.83
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol (2002) 0.83
Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet (2012) 0.83
The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. Br J Clin Pharmacol (2008) 0.83
Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res (2014) 0.82
Population pharmacokinetics of deferiprone in healthy subjects. Br J Clin Pharmacol (2014) 0.82
Quantitative analysis of rate and extent of tolerance of biomarkers: application to nicotinic acid-induced changes in non-esterified fatty acids in rats. Eur J Pharm Sci (2011) 0.82
Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. Br J Clin Pharmacol (2012) 0.82
Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res (2004) 0.82
Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res (2007) 0.82